Effect of Cyproterone Acetate Orally on Hair Density and Diameter and Endocrine Factors in Women with Idiopathic Hirsutism

Peereboom-Wynia, J. D. R.; Boekhorst, Jos

doi:10.1159/000250460

Cited by 13 publications

(3 citation statements)

References 22 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…52 Reasonably, treatment of hirsutism with the antiandrogen cyproterone acetate leads to significant reduction of hairiness. [57][58][59][60][61] Treatment with other antiandrogenic hormones or drugs for hirsutism has also been promising. 47,48 Androgens, however, show an entirely opposite effect on the scalp hair follicles.…”

Section: Androgen Action On Hair Growthmentioning

confidence: 99%

Biology of Hair Growth

Uno¹

1986

Semin Reprod Med

View full text Add to dashboard Cite

Section: Androgen Action On Hair Growthmentioning

confidence: 99%

Biology of Hair Growth

Uno¹

1986

Semin Reprod Med

View full text Add to dashboard Cite

“…The effects of CA on plasma testosterone levels has also to be clarified. Peereboom-Wynia et al 18) could find no correlation between the degree of hirsutism, the concentration of plasma testosterone, dehydroepiandrosterone sulphate and androstenedione before and after treatment. Tejero et al 19) however showed a significant reduction in the plasma testosterone levels in CA treated women who had raised pre-treatment levels.…”

Section: Discussionmentioning

confidence: 90%

The Management of Female Hirsutism with the Anti‐Androgen Agent Cyproterone

Kwok

Correy

Senator

1985

Asia-Oceania Journal of Obstetrics and Gynaecology

View full text Add to dashboard Cite

The treatment of female hirsutism with a combination of the anti-androgen agent Cyproterone Acetate and Ethinyl Oestradiol is discussed in 53 patients of whom 37 have completed 12 months' treatment. Assessment was carried out by serial scoring using the Ferriman and Gallwey method. The majority of patients experienced satisfactory subjective improvement, and objective improvement was recorded in approximately half of the patients who completed the full course of 12 months' treatment. Side effects of treatment were experienced by 27 of the 3 7 patients completing 12 months' treatment but in most instances were mild and related to the oestrogen. Minimal disturbances of liver function tests and lipids were noted which did not reach significance. The maximum response t o treatment was noted after 6 months of therapy, and it is recommended that this be the standard initial course of treatment. Key words: cyproterone acetate and ethinyl oestradiol, assessment of hirsutes. side effects o f treatment, horm o n e assays, biochemical assays

show abstract

“…They reported that the hirsutism score fell by 50% over 6 months, although in reporting their results the investigators did not differentiate between women with IH and PCOS. Peereboom-Wynia and Boekhorst (151) treated another 11 well defined women with IH using CPA,100 -200 mg, on days 5-15 and EE, 50 g, on days 5-26 of the cycle, and reported a reduction in the hair density and diameter (151). Overall, it would appear that CPA is effective in treating patients with IH, although larger studies are still lacking.…”

mentioning

confidence: 99%

Idiopathic Hirsutism

Azziz¹

2000

Endocrine Reviews

View full text Add to dashboard Cite

Hirsutism, the presence of terminal (coarse) hairs in females in a male-like pattern, affects between 5% and 10% of women. Of the sex steroids, androgens are the most important in determining the type and distribution of hairs over the human body. Under the influence of androgens hair follicles that are producing vellus-type hairs can be stimulated to begin producing terminal hairs (i.e., terminalized). The activity of local 5alpha-reductase (5alpha-RA) determines to a great extent the production of dihydrotestosterone (DHT), and consequently the effect of androgens on hair follicles. While there are two distinct 5alpha-RA isoenzymes, type 1 and type 2, the activity of these in the facial or abdominal skin of hirsute women remains to be determined. Although the definition of idiopathic hirsutism (IH) has been an evolving process, the diagnosis of IH should be applied only to hirsute patients with normal ovulatory function and circulating androgen levels. A history of regular menses is not sufficient to exclude ovulatory dysfunction, since up to 40% of eumenorrheic hirsute women are anovulatory. The diagnosis of IH, when strictly defined, will include less than 20% of all hirsute women. The pathophysiology of IH is presumed to be a primary increase in skin 5alpha-RA activity, probably of both isoenzyme types, and possibly an alteration in androgen receptor function. Therapeutically, these patients respond to antiandrogen or 5alpha-RA inhibitor therapy. Pharmacological suppression of ovarian or adrenal androgen secretion may be of additional, albeit limited, benefit. New therapeutic strategies such as laser epilation or the use of new biological response modifiers may play an important role in offering a more effective means of treatment to remove unwanted hair. Further investigations into the genetic, molecular, and metabolic aspects of this disorder, including only well defined patients, are needed.

show abstract

Effect of Cyproterone Acetate Orally on Hair Density and Diameter and Endocrine Factors in Women with Idiopathic Hirsutism

Cited by 13 publications

References 22 publications

Biology of Hair Growth

Biology of Hair Growth

The Management of Female Hirsutism with the Anti‐Androgen Agent Cyproterone

Idiopathic Hirsutism

Contact Info

Product

Resources

About